Perioperative use of tirofiban hydrochloride (Aggrastat) does not increase surgical bleeding after emergency or urgent coronary artery bypass grafting

Journal of Thoracic and Cardiovascular Surgery

Volumn 122, Issue 6, 2001, Pages 1181-1185

  Bizzarri, Federico ^a   Scolletta, Sabino ^a   Tucci, Enrico ^a   Lucidi, Mara ^a   Davoli, Giuseppe ^a   Toscano, Thomas ^a   Neri, Eugenio ^a   Muzzi, Luigi ^a   Frati, Giacomo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FRESH FROZEN PLASMA; HEMOGLOBIN; HEPARIN; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING TIME; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY THROMBOSIS; EMERGENCY SURGERY; ERYTHROCYTE CONCENTRATE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MALE; PARTIAL THROMBOPLASTIN TIME; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0035783622     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2001.117838     Document Type: Article

References (14)

1. The RESTORE Study Group. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-53.
2. Prism-Plus Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med. 1998;338:1488-97.
3. Dyke CM, Bhatia D, Lorenz TJ, et al. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. Ann Thorac Surg. 2000;70:866-72.
4. Dyke C, Bhatia D, Inhibitors of the platelet receptor glycoprotein IIb/IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon. J Cardiovasc Surg. 1999;40:505-16.
5. Dyke CM. Safety of glycoprotein IIb/IIIa inhibitors: A heart surgeon's perspective. Am Heart J. 1999;138:S307-16.
6. Hiramatsu Y, Gikakis N, Anderson HL 3rd, Gorman JH 3rd, Marcinkiewicz C, Gould RJ, et al. Tirofiban provides "platelet anesthesia" during cardiopulmonary bypass in baboons. J Thorac Cardiovasc Surg. 1997;113:182-93.
7. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA. 1992;267:2344-8.
8. Buckberg GD. Anterograde/retrograde blood cardioplegia to ensure cardioplegic distribution: Operative techniques and objectives. J Card Surg. 1989;4:216-38.
9. Buckberg GD. Strategies and logic of cardioplegic delivery to prevent, avoid and reverse ischemic and reperfusion damage. J Thorac Cardiovasc Surg. 1987;93:127-39.
10. Woodman RC, Harker LA. Bleeding complication associated with cardiopulmonary bypass. Blood. 1990;76:1680-97.
11. Chesebro JH, Fuster V. Thrombosis in unstable angina. N Engl J Med. 1992;327:192-4.
12. Koneti Rao A, Sun L, Hiramatsu Y, Gorman JH 3rd, Edmunds LH. Glycoprotein IIb/IIIa receptor antagonist tirofiban inhibits thrombin generation during cardiopulmonary bypass in baboons. Thromb Haemost. 1999;82:140-4.
13. Balhia D, Dyke C, Cook J, et al. The impact of abciximab (ReoPro) on bleeding after emergency coronary artery bypass grafting [abstract]. 11th Annual Update: Cardiac and General Thoracic Surgery. American College of Chest Physicians, 1999.
14. Lewis W, Collard CD. Does perioperative antithrombotic therapy increase the likelihood of a postoperative coagulopathy after cardiac surgery? Anesthesiology. 2000;92:1499-501.